- Home
- EYPT vs ALX Comparison
EYPT vs ALX Comparison
Compare EYPT & ALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | ALX |
|---|---|---|
| Founded | 1987 | 1928 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate Investment Trusts |
| Sector | Industrials | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | EYPT | ALX |
|---|---|---|
| Price | $12.86 | $243.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $31.80 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 51.1K |
| Earning Date | 03-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.50 |
| Revenue | $7,539,000.00 | ★ $213,183,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,031.72 | N/A |
| P/E Ratio | ★ N/A | $43.37 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.91 | $189.05 |
| 52 Week High | $19.11 | $260.84 |
Technical Indicators
Market Signals| Indicator | EYPT | ALX |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 53.75 |
| Support Level | $12.05 | $229.26 |
| Resistance Level | $13.32 | $248.48 |
| Average True Range (ATR) | 1.01 | 7.63 |
| MACD | -0.33 | 0.03 |
| Stochastic Oscillator | 3.45 | 65.50 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.